An Integrated Pathophysiological and Clinical Perspective of the Synergistic Effects of Obesity, Hypertension, and Hyperlipidemia on Cardiovascular Health: A Systematic Review

Abstract

This review paper explores the synergistic effects of obesity, hypertension (HTN), and hyperlipidemia on cardiovascular health by integrating pathophysiological and clinical perspectives. Obesity, characterized by excessive body fat, HTN, defined by elevated blood pressure, and hyperlipidemia, indicated by high blood lipid levels, are globally prevalent conditions that significantly increase the risk of cardiovascular diseases (CVDs). The interplay between these conditions exacerbates cardiovascular risk through mechanisms such as chronic inflammation, insulin resistance, endothelial dysfunction, arterial stiffness, and atherogenesis. This review synthesizes epidemiological evidence and highlights the prevalence and co-occurrence of these conditions, with an emphasis on their combined impact on cardiovascular health. The literature search encompassed various databases, and data extraction included key study characteristics and outcomes. The findings underscore the importance of integrated management strategies, involving lifestyle interventions, pharmacological treatments, and regular monitoring, to mitigate the heightened cardiovascular risk posed by these conditions. In addition, the various public health implications are addressed, advocating for community-based interventions and policy changes. Future research directions may include exploring novel therapeutic approaches, personalized medicine strategies, and longitudinal studies to enhance the understanding and management of the synergistic effects of obesity, HTN, and hyperlipidemia on cardiovascular health.

Introduction and background

Obesity, hypertension (HTN), and hyperlipidemia are three interconnected conditions with significant global prevalence and implications for public health [1-3]. Obesity is characterized by an excessive accumulation of body fat, typically defined by a body mass index (BMI) of 30 or higher [1-4]. The World Health Organization (WHO) estimates that more than 650 million adults worldwide were obese in 2016, with the prevalence rising rapidly across various regions, particularly in low- and middle-income countries [5]. Furthermore, it is noteworthy that, globally, while obesity prevalence has over doubled since 1990, adolescent obesity prevalence has quadrupled. Consequently, as of 2022, 2.5 billion adults (43%) aged 18 years and above were overweight, with 890 million (16%) of them being obese, even as 35 million children aged below five years were overweight [5]. Moreover, in 2022, more than 390 million children and adolescents aged between five and 19 years were overweight, with over 160 million of them being obese [5]. HTN, often termed the “silent killer,” is defined by consistently elevated blood pressure levels, specifically a systolic blood pressure of 130 mm Hg or higher and/or a diastolic blood pressure of 80 mm Hg or higher. HTN affects over 1.3 billion people globally, with significant variability in prevalence among different populations and regions [1]. Hyperlipidemia, characterized by elevated levels of lipids in the blood, including cholesterol and triglycerides, is a major risk factor for cardiovascular diseases (CVDs) [6]. The prevalence of hyperlipidemia varies widely but is notably high in populations with significant dietary and lifestyle risk factors [6]. In their study, Esteghamati et al. reported an obesity, HTN, and dyslipidemia prevalence of 22.3%, 25.2%, and 42.9%, respectively, highlighting the considerable burden of these conditions [2].

The public health significance of obesity, HTN, and hyperlipidemia cannot be overstated, given their roles as primary risk factors for CVD, the leading cause of death worldwide [1-3]. The growing epidemic of these conditions is driven by a combination of genetic, behavioral, and environmental factors [2]. Urbanization, sedentary lifestyles, and the global adoption of energy-dense, nutrient-poor diets contribute significantly to the rising prevalence of obesity, which in turn exacerbates the rates of HTN and hyperlipidemia [6]. Bozkurt et al. emphasize that the interplay between these conditions exacerbates the overall cardiovascular risk, creating a synergistic effect that amplifies morbidity and mortality [3]. The increasing prevalence of these conditions, particularly in younger age groups, poses a significant challenge for health systems worldwide, requiring comprehensive public health strategies to address lifestyle modifications, early diagnosis, and effective management.

This review explores the synergistic effects of obesity, HTN, and hyperlipidemia on cardiovascular health, providing a comprehensive understanding of how these conditions interact and amplify each other's impact. The pathophysiological mechanisms underlying this synergy involve complex interactions between metabolic, hormonal, and inflammatory pathways [7]. For instance, obesity-induced insulin resistance can lead to HTN through mechanisms such as increased sympathetic nervous system activity and sodium retention [2-4]. Concurrently, obesity contributes to hyperlipidemia by altering lipid metabolism, increasing triglycerides, and reducing high-density lipoprotein (HDL) cholesterol levels [2-4]. Wang et al. highlight that these interrelated processes can synergistically increase the risk of ischemic stroke, underscoring the importance of understanding these interactions for effective clinical management [4]. In addition to elucidating the pathophysiological mechanisms, this review will discuss epidemiological evidence highlighting the prevalence and co-occurrence of these conditions and their combined impact on cardiovascular health. Mohamed suggests that addressing these conditions through functional foods and dietary interventions can be a promising strategy, further highlighting the need for integrated approaches in management [8]. Epidemiological studies provide critical insights into the extent of the problem and identify key demographic and lifestyle factors contributing to the observed trends. This review will synthesize findings from various population-based studies to present a clear picture of the public health burden posed by these interrelated conditions.

Review

Materials and search strategy, data extraction, and synthesis

The literature search was conducted across several comprehensive databases, including the American Heart Association (AHA), PubMed, NIH, Cochrane Library, BMC, Frontiers, Oxford Academic, MDPI, and Elsevier, to gather relevant studies examining the interrelationship between obesity, HTN, and hyperlipidemia on cardiovascular health. Keywords used in the search strategy included “obesity,” “hypertension,” “hyperlipidemia,” and “cardiovascular health.” These terms were used both individually and in combination to ensure a broad and inclusive search of the existing literature. The review included cohort studies, randomized controlled trials (RCTs), and observational studies investigating the synergistic effects of obesity, HTN, and hyperlipidemia on cardiovascular health. The criteria for exclusion included non-human studies, non-English articles, studies without full text available, case reports, reviews, and editorials. In addition, studies with sample sizes of fewer than 50 participants, those with poor methodological quality, and studies published before 2000 were excluded to ensure the relevance and reliability of the included data. Data extraction included systematically examining each selected study to extract critical information about the synergistic effects of obesity, HTN, and hyperlipidemia on cardiovascular health. Key data points collected encompassed study characteristics (e.g., author(s), publication year, study design), participant characteristics (e.g., sample size, demographics), intervention details, and primary outcomes related to the interactions between obesity, HTN, and hyperlipidemia. The extraction process also involved documenting the statistical methods used and the results obtained, including association and effect size measures. Quality assessment was performed independently by two reviewers using standardized assessment tools to ensure the reliability and validity of the included studies. Randomized controlled trials were evaluated using the Cochrane Risk of Bias tool, which assesses various bias domains such as selection, performance, detection, attrition, and reporting biases. The extracted data were synthesized using qualitative methods. Qualitative synthesis involved thematic analysis to identify and examine recurrent themes and patterns across the studies, providing a comprehensive understanding of the synergistic effects of obesity, HTN, and hyperlipidemia on cardiovascular health. The synthesis provides a detailed understanding of the interactions and combined effects of obesity, HTN, and hyperlipidemia on cardiovascular health [9-11].

The in-depth search conducted on the various online databases led to the identification of a total of 500 studies. After removing the duplicates and screening titles and abstracts, 150 studies were assessed for eligibility based on full-text review. Finally, 50 studies met the inclusion criteria and were included in the systematic review. The study selection process for this review is presented in Figure 1.

The results of the Cochrane Risk of Bias tool analysis are presented in Table 2.

Discussion

Pathophysiological Mechanisms

Obesity significantly impacts cardiovascular health through various pathophysiological mechanisms, including chronic inflammation, insulin resistance, and endothelial dysfunction. Obesity is characterized by an excessive accumulation of adipose tissue, which secretes a range of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). These cytokines contribute to systemic inflammation and endothelial dysfunction, a critical factor in the development of atherosclerosis and cardiovascular disease [12]. In addition, obesity is closely linked to insulin resistance, a condition where cells fail to respond effectively to insulin, leading to elevated blood glucose levels. Hyperglycemia, which is due to insulin resistance, exacerbates oxidative stress by increasing reactive oxygen species (ROS) production within the endothelial cells [13]. Normally, oxidative stress damages the endothelial linings, which, in turn, worsens vascular dysfunction while simultaneously promoting atherosclerosis [13]

Insulin resistance further exacerbates cardiovascular risk by promoting dyslipidemia and HTN. Insulin-resistant states are associated with increased free fatty acid flux, contributing to lipid abnormalities and endothelial cell damage [10]. Furthermore, obesity-induced insulin resistance increases sympathetic nervous system activity and sodium retention, which elevates blood pressure [14]. The combination of these factors creates a vicious cycle where obesity, inflammation, and metabolic disturbances collectively enhance cardiovascular risk.

Obesity and Cardiovascular Health: HTN, Hyperlipidemia, and Cardiovascular Health

HTN adversely affects cardiovascular health through several pathophysiological pathways, notably arterial stiffness and left ventricular hypertrophy. Arterial stiffness, characterized by the reduced elasticity of large arteries, is a hallmark of HTN and contributes to increased cardiac workload and pressure. This condition is driven by structural changes in the arterial wall, including increased collagen deposition and reduced elastin content, which are often exacerbated by chronic high blood pressure [15]. The stiffening of arteries results in elevated systolic blood pressure and pulse pressure, promoting further cardiovascular damage. Left ventricular hypertrophy (LVH), another common consequence of HTN, involves the thickening of the heart's left ventricular wall as a compensatory response to increased vascular resistance and pressure overload. LVH is associated with impaired diastolic function, increased myocardial oxygen demand, and a higher risk of arrhythmias, all of which significantly elevate the risk of heart failure and other cardiovascular events [16]. Furthermore, endothelial dysfunction and increased oxidative stress, common in hypertensive individuals, exacerbate arterial damage and contribute to atherosclerosis development [17].

Hyperlipidemia plays a critical role in the pathogenesis of atherosclerosis and subsequent cardiovascular events through mechanisms such as plaque formation and oxidative stress. Elevated levels of low-density lipoprotein cholesterol (LDL-C) are particularly harmful, as LDL-C particles infiltrate the endothelial lining of arteries, becoming oxidized and initiating inflammatory processes that lead to plaque formation. The accumulation of lipid-laden macrophages, or foam cells, within the arterial wall is a key step in atherogenesis, eventually resulting in the development of fatty streaks and fibrous plaques [18]. Oxidative stress further contributes to the instability of these plaques by promoting the oxidation of LDL-C and the production of reactive oxygen species (ROS), which damage endothelial cells and smooth muscle cells within the vessel wall [18]. This oxidative damage not only accelerates plaque growth but also increases the risk of plaque rupture and thrombosis, leading to acute cardiovascular events such as myocardial infarction and stroke [19]. Hyperlipidemia-induced endothelial dysfunction, characterized by impaired nitric oxide bioavailability and increased endothelial cell permeability, also exacerbates the atherogenic process [20].

Synergistic Effects of Obesity, HTN, and Hyperlipidemia on Cardiovascular Health

The combined effects of obesity, HTN, and hyperlipidemia on cardiovascular health are substantial and additive, leading to compounded pathophysiological processes that significantly elevate cardiovascular risk. Each condition independently contributes to cardiovascular disease, but their co-occurrence creates a complex interplay that amplifies their individual effects. For instance, obesity exacerbates HTN through mechanisms such as increased sympathetic nervous system activity and insulin resistance, while hyperlipidemia accelerates atherogenesis by promoting lipid accumulation and oxidative stress. The presence of all three conditions leads to a heightened inflammatory state, with increased levels of pro-inflammatory cytokines and oxidative stress markers [21]. This inflammatory milieu contributes to endothelial dysfunction, arterial stiffness, and the progression of atherosclerosis. In addition, the metabolic disturbances associated with obesity and insulin resistance promote dyslipidemia and HTN, creating a vicious cycle that perpetuates cardiovascular damage [22]. The synergistic interaction between these conditions significantly increases the likelihood of adverse cardiovascular events, including myocardial infarction, stroke, and heart failure, underscoring the importance of integrated management strategies to address this triad of risk factors. The synergistic pathophysiological links between obesity, HTN, and hyperlipidemia are presented in Figure 2.

Epidemiological Evidence: Prevalence and Co-occurrence

The global prevalence of obesity, HTN, and hyperlipidemia is alarmingly high, reflecting significant public health challenges. According to recent estimates, over 1.9 billion adults were overweight, with more than 650 million classified as obese globally. HTN affects approximately 1.13 billion people worldwide, with the highest prevalence in low- and middle-income countries [1,5]. Hyperlipidemia, characterized by elevated levels of cholesterol and triglycerides, is a prevalent condition associated with an increased risk of cardiovascular diseases. In China, a large-scale cross-sectional study reported a co-prevalence of these conditions among adults with type 2 diabetes mellitus, highlighting the compounded risk they pose [22,23]. In the United States, Jain noted a significant overlap of obesity with conditions like diabetes, anemia, and HTN, further complicating management and treatment outcomes [21]. The co-occurrence of these conditions not only increases the individual risk of cardiovascular events but also poses a significant burden on healthcare systems globally [23-25]. Regional variations exist, with developing countries experiencing rapid increases due to urbanization and lifestyle changes. By contrast, developed countries continue to struggle with high prevalence rates due to persistent dietary and physical activity patterns.

Longitudinal Studies

Longitudinal studies have provided valuable insights into the combined impact of obesity, HTN, and hyperlipidemia on cardiovascular health. Cleven et al. conducted a systematic review of longitudinal studies and found a strong association between physical inactivity and the incidence of obesity, coronary heart disease, diabetes, and HTN [25]. These findings underscore the importance of lifestyle factors in the progression of these conditions and their combined effect on cardiovascular health. Chandrabose et al. highlighted the role of the built environment in influencing cardio-metabolic health through a meta-analysis of longitudinal studies, emphasizing how urban planning and access to recreational spaces can mitigate the risk factors associated with obesity, HTN, and hyperlipidemia [26]. Another significant study by Dayimu et al. examined lipid profile trajectories and their relationship with cardiovascular disease risk, revealing that persistent dyslipidemia significantly increases the risk of cardiovascular events over time [27]. Torky et al. focused on individuals with congenital adrenal hyperplasia. They found that longitudinal monitoring of cardiovascular risk factors, including obesity, HTN, and hyperlipidemia, is crucial for early intervention and management [28].

Population Studies

The key population-based studies that have highlighted the increased risk of cardiovascular events in persons with obesity, HTN, and hyperlipidemia have been presented in Table 2.

Clinical Implications: Diagnosis and Screening

Screening and early diagnosis of obesity, HTN, and hyperlipidemia are crucial for preventing cardiovascular diseases and managing these conditions effectively. According to the Canadian Journal of Cardiology, routine measurement of body mass index (BMI) and waist circumference is recommended for identifying obesity, as these metrics provide insights into overall and central adiposity, respectively [34]. Early diagnosis of HTN involves regular blood pressure monitoring, with thresholds for normal and elevated blood pressure well-defined in clinical guidelines. Home and ambulatory blood pressure monitoring is also recommended to obtain accurate measurements and detect white-coat HTN [35,36]. For hyperlipidemia, lipid profile assessments, including total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides, should be conducted regularly, especially in individuals with risk factors such as obesity and HTN [37]. The importance of screening for familial hypercholesterolemia, a genetic disorder that significantly elevates cholesterol levels, is highlighted by Alonso et al., who emphasize early intervention to prevent severe cardiovascular outcomes [38]. In addition, integrating metabolic syndrome criteria, which include measures of obesity, blood pressure, and lipid levels, can help identify individuals at high risk for cardiovascular diseases [39]. Early diagnosis and consistent monitoring are essential for timely intervention and effective management of these interrelated conditions.

Management Strategies

Effective management of obesity, HTN, and hyperlipidemia involves significant lifestyle modifications. Dietary changes, such as adopting a heart-healthy diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats, play a crucial role in managing these conditions [40]. Physical activity is another critical component, with the American Heart Association recommending at least 150 minutes of moderate-intensity exercise per week to improve cardiovascular health and aid in weight management [41]. Weight management programs that combine dietary changes, physical activity, and behavioral modifications effectively reduce obesity and associated cardiovascular risks [42].

Lifestyle Interventions, Pharmacological Treatments, and Integrated Approach

Pharmacological treatments are often necessary for managing HTN and hyperlipidemia, particularly when lifestyle modifications alone are insufficient. Antihypertensives, including ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, and diuretics, are commonly prescribed to control blood pressure and reduce the risk of cardiovascular events [43]. For hyperlipidemia, statins are the primary treatment to lower LDL-C levels and prevent atherosclerotic cardiovascular disease. In cases of combined dyslipidemia, additional lipid-lowering agents such as ezetimibe, PCSK9 inhibitors, and fibrates may be used [44]. Moreover, pharmacological treatments that include GLP-1 receptor agonists such as liraglutide and semaglutide have indicated effectiveness in attaining considerable weight loss and enhancing cardiovascular outcomes [44-46]. Such pharmacological treatments promote weight loss while also offering favorable effects with regard to blood pressure and glycemic control, which are considered vital to the management of hyperlipidemia and HTN. Furthermore, in instances of severe obesity, in which weight loss is unattainable through pharmacotherapy and lifestyle interventions, bariatric surgery has been used as an effective treatment for weight management [45]. Such surgical interventions often result in sustained weight loss, enhancement in various metabolic parameters, and considerable cardiovascular risk reduction. Further, an integrated approach that combines pharmacological treatments and lifestyle modifications, and when necessary, surgical interventions, is important in tackling the various synergistic effects of HTN, hyperlipidemia, and obesity on cardiovascular health [44, 45]. The coordination of such treatments enables healthcare providers to realize better long-term outcomes while reducing cardiovascular risk events in high-risk populations [45]. Thus, combination therapies are often required for patients with multiple risk factors to achieve optimal cardiovascular protection. This approach involves coordinated care that addresses all three conditions simultaneously through lifestyle interventions, pharmacological treatments, and regular monitoring. Integrated care models emphasize the importance of patient education, self-management, and multidisciplinary collaboration among healthcare providers [45]. Comprehensive cardiovascular rehabilitation programs that include exercise training, nutritional counseling, and psychosocial support have been shown to improve outcomes and reduce the recurrence of cardiovascular events [46]. Healthcare providers can ensure that all aspects of a patient's cardiovascular risk are addressed, leading to better long-term health outcomes and reduced healthcare costs [47].

Public Health Implications

Public health initiatives aimed at preventing obesity, HTN, and hyperlipidemia are crucial to mitigating the burden of cardiovascular diseases globally. Programs such as community health education campaigns, school-based interventions, and workplace wellness programs are essential in promoting healthy lifestyles. These initiatives focus on encouraging physical activity, balanced diets, and regular health screenings to detect and manage these conditions early [25]. Integrating these programs into primary healthcare services can ensure broader reach and sustainability, particularly in underserved communities. For example, initiatives like the Million Hearts campaign in the United States aim to prevent one million heart attacks and strokes within five years by implementing evidence-based interventions to improve cardiovascular health [48]. Moreover, addressing social determinants of health, such as access to healthy food and safe spaces for physical activity, is fundamental to these prevention strategies.

Prevention Strategies, Policy Recommendations, and Community and Environmental Interventions

To address the combined burden of obesity, HTN, and hyperlipidemia on public health systems, comprehensive policy changes are necessary. Policies that promote healthy eating through subsidies for fruits and vegetables, taxation of sugary drinks, and regulation of food marketing to children can significantly impact dietary habits [49]. In addition, implementing policies that encourage physical activity, such as developing pedestrian-friendly infrastructure and public recreational spaces, can help reduce the prevalence of these conditions [50]. Healthcare policies should also support regular screening and management of obesity, HTN, and hyperlipidemia through universal healthcare coverage and preventive care incentives. Strengthening surveillance systems to monitor the incidence and prevalence of these conditions and their risk factors is crucial for informed policy-making and resource allocation [49]. Community-based interventions and environmental modifications play a vital role in preventing and managing obesity, HTN, and hyperlipidemia. Community interventions, such as group-based exercise programs, nutrition workshops, and peer support groups, effectively promote lifestyle changes and improve health outcomes [51]. Environmental modifications, including creating parks, walking trails, and bike lanes, encourage physical activity by providing safe and accessible spaces for exercise [52]. In addition, local policies that support the establishment of farmers' markets and community gardens can improve access to fresh, healthy foods, thereby addressing dietary risk factors for these conditions [53, 54]. Collaborative efforts between public health agencies, local governments, and community organizations are essential to implement these interventions effectively and ensure their sustainability.

Strengths and Limitations

The study leverages its strengths in the comprehensive approach, as it assumes integrated clinical and pathophysiological perspectives, thereby offering a holistic perspective of the way the different factors interact. This provides a more comprehensive understanding of the various cardiovascular health risks. The other notable strength regards the observation that the study and its findings are evidence-based. Thus, the study has utilized an array of evidence sources, including epidemiological studies, cohort studies, systematic reviews, clinical data, and various medical databases, which enables it to offer well-rounded perspectives supported by adequate and diverse evidence. The other notable strength of this study regards cross-disciplinary insights, as the study has integrated findings from divergent studies and fields, which enables it to provide novel insights and interventional strategies. Nevertheless, a number of potential limitations have been acknowledged including the existence of potential for confounding variables. For instance, other notable risk factors, including physical inactivity, genetic predispositions, and smoking, are likely to confound synergistic effects thereby making it increasingly challenging to effectively isolate the contributions attributable to HTN, obesity, and hyperlipidemia. Consequently, the measurement challenges are considered potential limitations in this study, given that the measurement of the combined effects of several risk factors, including HTN, obesity, and hyperlipidemia, in a manner that precisely reflects the real-world clinical results might be difficult. Challenges may be experienced in the separation of correlations from the causations.

Conclusions

The synergistic effects of obesity, HTN, and hyperlipidemia significantly elevate the risk of cardiovascular diseases through complex interactions involving chronic inflammation, insulin resistance, endothelial dysfunction, arterial stiffness, and atherogenesis. Individually, each condition poses substantial health risks, but their combined presence amplifies these risks, leading to a higher incidence of myocardial infarction, stroke, and heart failure. This review underscores the importance of understanding these interrelated pathophysiological mechanisms to develop effective prevention and management strategies. Integrated management and prevention strategies are crucial to reducing modifiable cardiovascular risks associated with obesity, HTN, and hyperlipidemia. The coordinated efforts of healthcare providers, policymakers, and communities are essential to mitigate the global burden of these interrelated conditions. Future research should focus on novel therapeutic approaches that address the combined effects of obesity, HTN, and hyperlipidemia. This includes investigating the efficacy of combination therapies and personalized medicine strategies that tailor treatments based on individual risk profiles. Longitudinal studies are needed to evaluate the long-term effectiveness of integrated management strategies and community-based interventions.